Philip R Spradling1, Lisa R Bulkow2, Susan E Negus3, Chriss Homan3, Michael G Bruce2, Brian J McMahon2,3. 1. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA. 2. Arctic Investigations Program, Division of Preparedness and Emerging Infectious Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK. 3. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK.
Abstract
UNLABELLED: The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti-HAV at intervals through age 15-16 years among three groups of Alaskan Native children who initiated a two-dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti-HAV status. Seropositivity (anti-HAV ≥20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty-three children participated in the study; follow-up did not differ significantly by vaccine group or maternal anti-HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15-16 years among group 1 children, who initiated vaccination at age 6 months (50%-75%), and among maternal anti-HAV-positive children in groups 2 and 3 (67%-87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti-HAV seropositivity should persist for ≥30 years after vaccination in 64% of all participants; among those seropositive at age 15-16 years, 84% were predicted to remain so for ≥30 years. CONCLUSION: Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15-16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody-positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow-up of this cohort.
RCT Entities:
UNLABELLED: The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti-HAV at intervals through age 15-16 years among three groups of Alaskan Native children who initiated a two-dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti-HAV status. Seropositivity (anti-HAV ≥20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty-three children participated in the study; follow-up did not differ significantly by vaccine group or maternal anti-HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15-16 years among group 1 children, who initiated vaccination at age 6 months (50%-75%), and among maternal anti-HAV-positive children in groups 2 and 3 (67%-87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti-HAV seropositivity should persist for ≥30 years after vaccination in 64% of all participants; among those seropositive at age 15-16 years, 84% were predicted to remain so for ≥30 years. CONCLUSION: Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15-16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody-positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow-up of this cohort.
Authors: R Dagan; J Amir; A Mijalovsky; I Kalmanovitch; A Bar-Yochai; S Thoelen; A Safary; S Ashkenazi Journal: Pediatr Infect Dis J Date: 2000-11 Impact factor: 2.129
Authors: Beth P Bell; Susan Negus; Anthony E Fiore; Julia Plotnik; Kathy Boaz Dhotre; James Williams; Craig N Shapiro; Brian J McMahon Journal: Pediatr Infect Dis J Date: 2007-02 Impact factor: 2.129
Authors: M Piazza; A Safary; A Vegnente; R Soncini; P Pensati; M Sardo; R Orlando; G Tosone; L Picciotto Journal: Vaccine Date: 1999-02-12 Impact factor: 3.641
Authors: G William Letson; Craig N Shapiro; Deborah Kuehn; Charlotte Gardea; Thomas K Welty; David S Krause; Stephen B Lambert; Harold S Margolis Journal: J Pediatr Date: 2004-03 Impact factor: 4.406
Authors: P Van Damme; J Banatvala; O Fay; S Iwarson; B McMahon; K Van Herck; D Shouval; P Bonanni; B Connor; G Cooksley; G Leroux-Roels; F Von Sonnenburg Journal: Lancet Date: 2003-09-27 Impact factor: 79.321
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03
Authors: Anke L Stuurman; Cinzia Marano; Eveline M Bunge; Laurence De Moerlooze; Daniel Shouval Journal: Hum Vaccin Immunother Date: 2016-10-27 Impact factor: 3.452